Julia Beck, Margret Rave-Fraenk, et al. “Prognostic value of cell-free DNA in patients with oropharyngeal cancers”, J Clin Oncol 34, 2016 (suppl; abstr e17511).

Tumor derived plasma cell-free DNA (TcfDNA) is described as biomarker to monitor tumor burden in cancer. Large somatic genome aberrations are hallmarks of malignancies and detectable in cfDNA. However, levels of TcfDNA are variable according to cancer types. We obtained copy-number instability (CNI) scores of cfDNA in treatment-naïve head and neck cancers before and after therapy.

Read the full text on: http://meetinglibrary.asco.org/content/167594-176